Seeking Alpha

Alnylam Pharmaceuticals extends gains after Leerink hikes price target

  • It's a banner day for sell-side billion dollar biotech bumps, writes theStreet's Adam Feuerstein, citing price target hikes from Leerink and BMO for Celldex Therapeutics (CLDX +11.2%) and Isis Pharmaceuticals (ISIS +7.3%) respectively.
  • Add Alnylam Pharmaceuticals (ALNY +7.1%) to the party, as Leerink's Marko Kozul ups his price target to $80 from $57.59 citing today's TTR-mediated amyloidosis data.
  • "Full ALN-TTR-SC (amyloidosis) data incrementally derisk both TTR-SC and ALNY's near term clinical pipeline programs," Kozul notes.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs